Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today ...
Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...
Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial ...
For most of the last few decades, AI has over-promised and under-delivered. However, behind the scenes, very significant advances in deep learning technologies have had a revolutionary impact within ...
The trial aims to enrol NSCLC patients who have not responded to frontline platinum-based and immune checkpoint inhibitor therapies. Credit: New Africa/Shutterstock. Genelux has dosed the first ...
A systematic understanding of the importance of disruptive business models and emerging technologies in manufacturing is needed and the MA Innovative Fashion Production offers a real opportunity for ...